Search Result

Results for "

Lewy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Biochemical Assay Reagents (1) Endogenous Metabolite (5) Epoxide Hydrolase (1) FBPase (1) Fluorescent Dye (1) iGluR (2) Liposome (1) nAChR (1) Phosphodiesterase (PDE) (3) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (1) α-synuclein (3)
By Research Areas:	Metabolic Disease (3) Neurological Disease (18)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135653A

(Rac)-EC5026 (Rac)-BPN-19186	Epoxide Hydrolase	Neurological Disease
(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a K_i of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB) .

HY-170035

GlcCer (d18:1/18:0) C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine	Liposome	Neurological Disease
GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipid. GlcCer (d18:1/18:0) is promising for research of Parkinson disease and dementia with Lewy bodies .

HY-160116

α-Synuclein aggregate binder 1	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

HY-113228

Isocitric acid 2 Publications Verification	Endogenous Metabolite	Neurological Disease
Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia .

HY-113228R

Isocitric acid (Standard)	Reference Standards Endogenous Metabolite	Neurological Disease
Isocitric acid (Standard) is the analytical standard of Isocitric acid (HY-113228). This product is intended for research and analytical applications. Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia.

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-156634

Risevistinel NYX-783	iGluR	Neurological Disease
Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-156626

Nevadistinel NYX-458; NYX-3054	iGluR	Neurological Disease
Nevadistinel (NYX-458; NYX-3054) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-108227

Quetiapine sulfone	5-HT Receptor	Neurological Disease
Quetiapine sulfone is a main metabolite of Quetiapine (HY-14544). Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist .

HY-153127

Florbenazine AV-133	Biochemical Assay Reagents	Neurological Disease
Florbenazine (AV-133) is a diagnostic imaging agent targeting the central nervous system monoamine transporter VMAT2, and its F-18 labeled form can be used for PET scanning. The biodistribution of [18F]Florbenazine in mice shows a high striatum/cerebellum ratio (0.48), which can be used for the diagnostic research of neurodegenerative diseases (including dementia with Lewy bodies and Parkinson's disease) .

HY-148325

α7 Nicotinic receptor agonist-1	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-113407A

D-Fructose-6-phosphate disodium	Endogenous Metabolite FBPase	Neurological Disease Metabolic Disease
D-Fructose 6-phosphate disodium is an endogenous metabolite. D-Fructose 6-phosphate disodium can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate disodium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate disodium can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate can be used to study Lewy body dementia.

HY-W725496

D-Fructose 6-phosphate dipotassium	Endogenous Metabolite	Neurological Disease Metabolic Disease
D-Fructose 6-phosphate dipotassium is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose 6-phosphate dipotassium can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose 6-phosphate dipotassium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate dipotassium can be used to study Lewy body dementia .

HY-113407

D-Fructose-6-phosphate	Endogenous Metabolite	Neurological Disease Metabolic Disease
D-Fructose 6-phosphate is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose-6-phosphate is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate can be used to study Lewy body dementia .

HY-132821B

(R)-Irsenontrine (R)-E2027	Phosphodiesterase (PDE)	Neurological Disease
(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine (HY-132821), is a potent phosphodiesterase 9 (PDE9) inhibitor with an IC₅₀ value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases .

HY-132821A

Irsenontrine maleate E2027 maleate	Phosphodiesterase (PDE)	Neurological Disease
Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases .

HY-132821

Irsenontrine E2027	Phosphodiesterase (PDE)	Neurological Disease
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases .

Cat. No.	Product Name	Type

HY-W725496

D-Fructose 6-phosphate dipotassium	Carbohydrates
D-Fructose 6-phosphate dipotassium is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose 6-phosphate dipotassium can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose 6-phosphate dipotassium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate dipotassium can be used to study Lewy body dementia .

D-Fructose 6-phosphate dipotassium

Carbohydrates

D-Fructose 6-phosphate dipotassium is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose 6-phosphate dipotassium can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose 6-phosphate dipotassium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate dipotassium can be used to study Lewy body dementia .

Cat. No.	Product Name	Target	Research Area

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

Isocitric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Isocitric acid (Standard) is the analytical standard of Isocitric acid (HY-113228). This product is intended for research and analytical applications. Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia.

D-Fructose-6-phosphate disodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite FBPase
D-Fructose 6-phosphate disodium is an endogenous metabolite. D-Fructose 6-phosphate disodium can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate disodium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate disodium can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate can be used to study Lewy body dementia.

D-Fructose-6-phosphate	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Endogenous Metabolite
D-Fructose 6-phosphate is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose-6-phosphate is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate can be used to study Lewy body dementia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks